0
Startups & Venture·November 16, 2026·1 min read

Flagship’s Afeyan Sees UK Bet Creating Next Moderna

Share

Flagship planning up to £600m for a UK company-creation hub is a bet that the next Moderna-scale platform can be built on British science plus US-style venture formation. Biotech and deeptech founders in Europe should treat this as a new gravitational center—IP, talent, and regulators will cluster around wherever Flagship plants its first few companies.